Is GATTEX FDA approved?

Prior to this approval, options for treating SBS in children were limited and often involved invasive procedures or had suboptimal outcomes. The introduction of GATTEX® as a therapeutic option represents a major step forward in the care of these patients.

GATTEX® is a synthetic version of a naturally occurring hormone called glucagon-like peptide-2 (GLP-2). By mimicking the effects of GLP-2, GATTEX® helps to stimulate the growth and function of the intestinal lining, allowing for improved nutrient absorption and a reduction in the symptoms associated with SBS.

The FDA's decision to approve GATTEX® for use in children with SBS was based on the results of a clinical trial that demonstrated the drug's safety and efficacy in this patient population. The study showed that children treated with GATTEX® experienced improvements in weight gain, growth, and overall intestinal function.

The United States Food and Drug Administration (FDA) has recently announced a significant breakthrough in the treatment of Short Bowel Syndrome (SBS) in children. The agency has granted approval for the use of GATTEX® (teduglutide) in children aged one year and older who are living with this challenging condition.

BTCC, a leading cryptocurrency exchange, offers a range of services that cater to the needs of both individual and institutional investors. Among these services are spot trading, which allows users to buy and sell digital assets at the current market price, and futures trading, which enables traders to speculate on the future price movements of cryptocurrencies.